litlas
Log inCreate account

David M. Barrett

Active 1980–2025

102
Papers
27,876
Citations
77
h-index
102
i10-index

Citations

Citations per year for David M. Barrett1984: 2 citations1985: 2 citations1986: 2 citations1987: 8 citations1988: 10 citations1989: 7 citations1990: 10 citations1991: 14 citations1992: 11 citations1993: 11 citations1994: 11 citations1995: 23 citations1996: 36 citations1997: 36 citations1998: 48 citations1999: 36 citations2000: 36 citations2001: 47 citations2002: 34 citations2003: 31 citations2004: 35 citations2005: 61 citations2006: 40 citations2007: 32 citations2008: 31 citations2009: 21 citations2010: 14 citations2011: 16 citations2012: 26 citations2013: 102 citations2014: 154 citations2015: 329 citations2016: 435 citations2017: 529 citations2018: 638 citations2019: 1,378 citations2020: 1,721 citations2021: 1,574 citations2022: 1,206 citations2023: 1,017 citations2024: 1,362 citations2025: 769 citations2026: 25 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,938 citing papers, 34.9% of this breakdownChina: 1,438 citing papers, 12.7% of this breakdownGermany: 767 citing papers, 6.8% of this breakdownUnited Kingdom: 553 citing papers, 4.9% of this breakdownItaly: 449 citing papers, 4% of this breakdownFrance: 355 citing papers, 3.1% of this breakdownCanada: 327 citing papers, 2.9% of this breakdownSwitzerland: 283 citing papers, 2.5% of this breakdownSpain: 282 citing papers, 2.5% of this breakdownAustralia: 236 citing papers, 2.1% of this breakdownNetherlands: 236 citing papers, 2.1% of this breakdownJapan: 210 citing papers, 1.8% of this breakdown
0%34.9%Other 19.7%

Institutions

Fields

  • Medicine84.3%
  • Biochemistry, Genetics and Molecular Biology7.8%
  • Immunology and Microbiology5.4%
  • Engineering1.1%
  • Materials Science0.3%
  • Neuroscience0.3%
  • Other0.8%

Topics

  • CAR-T cell therapy research22.1%
  • Immune Cell Function and Interaction6.4%
  • Virus-based gene therapy research6.2%
  • Nanowire Synthesis and Applications4.6%
  • Immunotherapy and Immune Responses4.5%
  • Viral Infectious Diseases and Gene Expression in Insects3.2%
  • Other53%

Coauthors

All papers

Open in search
  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

    Authors: Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw, Richard Aplenc, David M. Barrett, Nancy Bunin, Anne Chew, Vanessa Gonzalez, Zhaohui Zheng, Simon F. Lacey, Yolanda D. Mahnke, J. Joseph Melenhorst, Susan R. Rheingold, Angela Shen, David T. Teachey, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp - New England Journal of Medicine 2014 cited by 5,408

  2. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

    Authors: Stephan A. Grupp, Michael Kalos, David M. Barrett, Richard Aplenc, David L. Porter, Susan R. Rheingold, David T. Teachey, Anne Chew, Bernd Hauck, J. Fraser Wright, Michael C. Milone, Bruce L. Levine, Carl H. June - New England Journal of Medicine 2013 cited by 3,491

  3. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

    Authors: Stephen Bagley, Meghan Logun, Joseph A. Fraietta, Xin Wang, Arati Desai, Linda J. Bagley, Ali Nabavizadeh, Danuta Jarocha, Rene Martins, Eileen Maloney, Lester Lledo, Carly Stein, Amy Marshall, Rachel Leskowitz, Julie K. Jadlowsky, Shannon Christensen, Bike Su Oner, Gabriela Plesa, Andrea Brennan, Vanessa Gonzalez, Fang Chen, Yusha Sun, Whitney L. Gladney, David M. Barrett, MacLean P. Nasrallah, Wei‐Ting Hwang, Guo‐li Ming, Hongjun Song, Donald L. Siegel, Carl H. June, Elizabeth O. Hexner, Zev A. Binder, Donald M. O’Rourke - Nature Medicine 2024 cited by 336

  4. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

    Authors: Elena Sotillo, David M. Barrett, Kathryn L. Black, Asen Bagashev, Derek A. Oldridge, Glendon Wu, Robyn T. Sussman, Claudia Lanauze, Marco Ruella, Matthew R. Gazzara, Nicole M. Martínez, Colleen T. Harrington, Elaine Y. Chung, Jessica Perazzelli, Ted J. Hofmann, Shannon L. Maude, Pichai Raman, Alejandro Barrera, Saar Gill, Simon F. Lacey, Jan J. Melenhorst, David Allman, Elad Jacoby, Terry J. Fry, Crystal L. Mackall, Yoseph Barash, Kristen W. Lynch, John M. Maris, Stephan A. Grupp, Andrei Thomas‐Tikhonenko - Cancer Discovery 2015 cited by 1,254

  5. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

    Authors: David T. Teachey, Simon F. Lacey, Pamela A. Shaw, J. Joseph Melenhorst, Shannon L. Maude, Noelle V. Frey, Edward Pequignot, Vanessa Gonzalez, Fang Chen, Jeffrey Finklestein, David M. Barrett, Scott L. Weiss, Julie C. Fitzgerald, Robert A. Berg, Richard Aplenc, Colleen Callahan, Susan R. Rheingold, Zhaohui Zheng, Stefan Rose‐John, Jason C. White, Farzana Nazimuddin, Gerald Wertheim, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp - Cancer Discovery 2016 cited by 1,084

  6. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

    Authors: Marco Ruella, Jun Xu, David M. Barrett, Joseph A. Fraietta, Tyler J. Reich, David E Ambrose, Michael Klichinsky, Olga Shestova, Prachi Patel, Irina Kulikovskaya, Farzana Nazimuddin, Vijay Bhoj, Elena J. Orlando, Terry J. Fry, Hans Bitter, Shannon L. Maude, Bruce L. Levine, Christopher L. Nobles, Frederic D. Bushman, Regina M. Young, John Scholler, Saar Gill, Carl H. June, Stephan A. Grupp, Simon F. Lacey, J. Joseph Melenhorst - Nature Medicine 2018 cited by 645

  7. Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy

    Authors: Gregory M. Chen, Changya Chen, Rajat K. Das, Peng Gao, Chia‐Hui Chen, Shovik Bandyopadhyay, Yangyang Ding, Yasin Uzun, Wenbao Yu, Qin Zhu, Regina M. Myers, Stephan A. Grupp, David M. Barrett, Kai Tan - Cancer Discovery 2021 cited by 205

  8. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL

    Authors: Zhiliang Bai, Steven Woodhouse, Ziran Zhao, Rahul Singh Arya, Kiya W. Govek, Dongjoo Kim, Stefan Lundh, Alev Baysoy, Hongxing Sun, Yanxiang Deng, Yang Xiao, David M. Barrett, Regina M. Myers, Stephan A. Grupp, Carl H. June, Rong Fan, Pablo G. Cámara, J. Joseph Melenhorst - Science Advances 2022 cited by 161

  9. Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

    Authors: Saba Ghassemi, Selene Nuñez-Cruz, Roddy S. O’Connor, Joseph A. Fraietta, Prachi Patel, John Scholler, David M. Barrett, Stefan Lundh, Megan M. Davis, Felipe Bedoya, Changfeng Zhang, John Leferovich, Simon F. Lacey, Bruce L. Levine, Stephan A. Grupp, Carl H. June, J. Joseph Melenhorst, Michael C. Milone - Cancer Immunology Research 2018 cited by 302

  10. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies

    Authors: Marco Ruella, David M. Barrett, Saad S. Kenderian, Olga Shestova, Ted J. Hofmann, Jessica Perazzelli, Michael Klichinsky, Vania Aikawa, Farzana Nazimuddin, Miroslaw Kozlowski, John Scholler, Simon F. Lacey, J. Joseph Melenhorst, Jennifer J.D. Morrissette, David A. Christian, Christopher A. Hunter, Michael Kalos, David L. Porter, Carl H. June, Stephan A. Grupp, Saar Gill - Journal of Clinical Investigation 2016 cited by 555

  11. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

    Authors: Julie C. Fitzgerald, Scott L. Weiss, Shannon L. Maude, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Pamela A. Shaw, Robert A. Berg, Carl H. June, David L. Porter, Noelle V. Frey, Stephan A. Grupp, David T. Teachey - Critical Care Medicine 2016 cited by 455

  12. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells

    Authors: Nathan Singh, Noelle V. Frey, Boris Engels, David M. Barrett, Olga Shestova, Pranali Ravikumar, Katherine D. Cummins, Yong Gu Lee, Raymone Pajarillo, Inkook Chun, Amy Shyu, Steven L. Highfill, Andrew Price, Linlin Zhao, Liaomin Peng, Brian Granda, Melissa Ramones, Xueqing Maggie Lu, David A. Christian, Jessica Perazzelli, Simon F. Lacey, Nathan H. Roy, Janis K. Burkhardt, Florent Colomb, Mohammad Damra, Mohamed Abdel‐Mohsen, Ting Liu, Dongfang Liu, Daron M. Standley, Regina M. Young, Jennifer L. Brogdon, Stephan A. Grupp, Carl H. June, Shannon L. Maude, Saar Gill, Marco Ruella - Nature Medicine 2021 cited by 202

  13. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model

    Authors: Sarah A. Richman, Selene Nuñez-Cruz, Babak Moghimi, Lucy Z. Li, Zachary T. Gershenson, Zissimos P. Mourelatos, David M. Barrett, Stephan A. Grupp, Michael C. Milone - Cancer Immunology Research 2017 cited by 268

  14. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

    Authors: Stephan Kadauke, Regina M. Myers, Yimei Li, Richard Aplenc, Diane Baniewicz, David M. Barrett, Allison Barz Leahy, Colleen Callahan, J. Gregory Dolan, Julie C. Fitzgerald, Whitney L. Gladney, Simon F. Lacey, Hongyan Liu, Shannon L. Maude, Regina McGuire, Laura Motley, David T. Teachey, Gerald Wertheim, Lisa Wray, Amanda M. DiNofia, Stephan A. Grupp - Journal of Clinical Oncology 2021 cited by 212

  15. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

    Authors: Regina M. Myers, Yimei Li, Allison Barz Leahy, David M. Barrett, David T. Teachey, Colleen Callahan, Christina Fasano, Susan R. Rheingold, Amanda M. DiNofia, Lisa Wray, Richard Aplenc, Diane Baniewicz, Hongyan Liu, Pamela A. Shaw, Edward Pequignot, Kelly Getz, Jennifer L. Brogdon, Andrew D. Fesnak, Donald L. Siegel, Megan M. Davis, Chelsie Bartoszek, Simon F. Lacey, Elizabeth O. Hexner, Anne Chew, Gerald Wertheim, Bruce L. Levine, Carl H. June, Stephan A. Grupp, Shannon L. Maude - Journal of Clinical Oncology 2021 cited by 187

  16. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

    Authors: Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, Rachelle Tibbetts, Long Hung, Hamid Bassiri, Michael D. Hogarty, David M. Barrett, Hiroyuki Shimada, Shahab Asgharzadeh - Nature Communications 2021 cited by 156

  17. Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers

    Authors: Rajat K. Das, Lauren Vernau, Stephan A. Grupp, David M. Barrett - Cancer Discovery 2019 cited by 249

  18. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

    Authors: David T. Teachey, Susan R. Rheingold, Shannon L. Maude, Gerhard Zugmaier, David M. Barrett, Alix E. Seif, Kim E. Nichols, Erica Suppa, Michael Kalos, Robert A. Berg, Julie C. Fitzgerald, Richard Aplenc, Lia Gore, Stephan A. Grupp - Blood 2013 cited by 617

  19. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

    Authors: Waleed Haso, Daniel W. Lee, Nirali N. Shah, Maryalice Stetler‐Stevenson, Constance M. Yuan, Ira Pastan, Dimiter S. Dimitrov, Richard A. Morgan, David J. FitzGerald, David M. Barrett, Alan S. Wayne, Crystal L. Mackall, Rimas J. Orentas - Blood 2012 cited by 583

  20. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

    Authors: Nathan Singh, Jessica Perazzelli, Stephan A. Grupp, David M. Barrett - Science Translational Medicine 2016 cited by 297

  21. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

    Authors: Shannon L. Maude, David M. Barrett, David T. Teachey, Stephan A. Grupp - The Cancer Journal 2014 cited by 758

  22. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome

    Authors: Chelsea Kotch, David M. Barrett, David T. Teachey - Expert Review of Clinical Immunology 2019 cited by 327

  23. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

    Authors: Joseph A. Fraietta, Kyle A. Beckwith, Prachi Patel, Marco Ruella, Zhaohui Zheng, David M. Barrett, Simon F. Lacey, J. Joseph Melenhorst, Shannon E. McGettigan, Danielle Cook, Changfeng Zhang, Jun Xu, Priscilla Do, Jessica Hulitt, Sagar B. Kudchodkar, Alexandria P. Cogdill, Saar Gill, David L. Porter, Jennifer A. Woyach, Meixiao Long, Amy J. Johnson, Kami J. Maddocks, Natarajan Muthusamy, Bruce L. Levine, Carl H. June, John C. Byrd, Marcela V. Maus - Blood 2016 cited by 461

  24. Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19

    Authors: Caroline Diorio, Rawan Shraim, Regina M. Myers, Edward M. Behrens, Scott Canna, Hamid Bassiri, Richard Aplenc, Chakkapong Burudpakdee, Fang Chen, Amanda M. DiNofia, Saar Gill, Vanessa Gonzalez, Michele P. Lambert, Allison Barz Leahy, Bruce L. Levine, Robert B. Lindell, Shannon L. Maude, J. Joseph Melenhorst, Haley Newman, Jessica Perazzelli, Alix E. Seif, Simon F. Lacey, Carl H. June, David M. Barrett, Stephan A. Grupp, David T. Teachey - Clinical Cancer Research 2022 cited by 65